As New Biosimilars Roll Out, Indian Biotech Group Raises Quality Concerns
This article was originally published in PharmAsia News
Executive Summary
Leading biotech group ABLE cautioned the government that India should not become a dumping ground for low-quality biosimilar products. The group pointed at several concerns related to Cipla’s latest launch of Enbrel copies.